411 related articles for article (PubMed ID: 34117234)
21. An accurate fully automated panel of plasma biomarkers for Alzheimer's disease.
Palmqvist S; Stomrud E; Cullen N; Janelidze S; Manuilova E; Jethwa A; Bittner T; Eichenlaub U; Suridjan I; Kollmorgen G; Riepe M; von Arnim CAF; Tumani H; Hager K; Heidenreich F; Mattsson-Carlgren N; Zetterberg H; Blennow K; Hansson O
Alzheimers Dement; 2023 Apr; 19(4):1204-1215. PubMed ID: 35950735
[TBL] [Abstract][Full Text] [Related]
22. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
[TBL] [Abstract][Full Text] [Related]
23. Optimal combinations of CSF biomarkers for predicting cognitive decline and clinical conversion in cognitively unimpaired participants and mild cognitive impairment patients: A multi-cohort study.
Salvadó G; Larsson V; Cody KA; Cullen NC; Jonaitis EM; Stomrud E; Kollmorgen G; Wild N; Palmqvist S; Janelidze S; Mattsson-Carlgren N; Zetterberg H; Blennow K; Johnson SC; Ossenkoppele R; Hansson O
Alzheimers Dement; 2023 Jul; 19(7):2943-2955. PubMed ID: 36648169
[TBL] [Abstract][Full Text] [Related]
24. Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition.
Cullen NC; Mälarstig AN; Stomrud E; Hansson O; Mattsson-Carlgren N
Sci Rep; 2021 Jan; 11(1):1965. PubMed ID: 33479445
[TBL] [Abstract][Full Text] [Related]
25. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
Brickman AM; Manly JJ; Honig LS; Sanchez D; Reyes-Dumeyer D; Lantigua RA; Lao PJ; Stern Y; Vonsattel JP; Teich AF; Airey DC; Proctor NK; Dage JL; Mayeux R
Alzheimers Dement; 2021 Aug; 17(8):1353-1364. PubMed ID: 33580742
[TBL] [Abstract][Full Text] [Related]
26. Combined plasma biomarkers for diagnosing mild cognition impairment and Alzheimer's disease.
Chiu MJ; Yang SY; Horng HE; Yang CC; Chen TF; Chieh JJ; Chen HH; Chen TC; Ho CS; Chang SF; Liu HC; Hong CY; Yang HC
ACS Chem Neurosci; 2013 Dec; 4(12):1530-6. PubMed ID: 24090201
[TBL] [Abstract][Full Text] [Related]
27. Potential Value of Plasma Amyloid-β, Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease.
Shi Y; Lu X; Zhang L; Shu H; Gu L; Wang Z; Gao L; Zhu J; Zhang H; Zhou D; Zhang Z
ACS Chem Neurosci; 2019 Aug; 10(8):3479-3485. PubMed ID: 31145586
[TBL] [Abstract][Full Text] [Related]
28. Predictive Accuracy of Blood-Derived Biomarkers for Amyloid-β Brain Deposition Along with the Alzheimer's Disease Continuum: A Systematic Review.
Cianflone A; Coppola L; Mirabelli P; Salvatore M
J Alzheimers Dis; 2021; 84(1):393-407. PubMed ID: 34542072
[TBL] [Abstract][Full Text] [Related]
29. Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer's Disease.
Lantero-Rodriguez J; Salvadó G; Snellman A; Montoliu-Gaya L; Brum WS; Benedet AL; Mattsson-Carlgren N; Tideman P; Janelidze S; Palmqvist S; Stomrud E; Ashton NJ; Zetterberg H; Blennow K; Hansson O
Mol Neurodegener; 2024 Feb; 19(1):19. PubMed ID: 38365825
[TBL] [Abstract][Full Text] [Related]
30. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Aβ-PET and cognition.
Rauchmann BS; Schneider-Axmann T; Perneczky R;
J Neurol Neurosurg Psychiatry; 2021 Dec; 92(12):1289-1295. PubMed ID: 34187867
[TBL] [Abstract][Full Text] [Related]
31. Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease.
Lin SY; Lin KJ; Lin PC; Huang CC; Chang CC; Lee YC; Hsiao IT; Yen TC; Huang WS; Yang BH; Wang PN
Alzheimers Res Ther; 2019 Dec; 11(1):111. PubMed ID: 31881963
[TBL] [Abstract][Full Text] [Related]
32. Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease.
Mengel D; Janelidze S; Glynn RJ; Liu W; Hansson O; Walsh DM
Ann Neurol; 2020 Nov; 88(5):878-892. PubMed ID: 32829532
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC
JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632
[TBL] [Abstract][Full Text] [Related]
34. High performance plasma amyloid-β biomarkers for Alzheimer's disease.
Nakamura A; Kaneko N; Villemagne VL; Kato T; Doecke J; Doré V; Fowler C; Li QX; Martins R; Rowe C; Tomita T; Matsuzaki K; Ishii K; Ishii K; Arahata Y; Iwamoto S; Ito K; Tanaka K; Masters CL; Yanagisawa K
Nature; 2018 Feb; 554(7691):249-254. PubMed ID: 29420472
[TBL] [Abstract][Full Text] [Related]
35. Comparison of plasma biomarkers and amyloid PET for predicting memory decline in cognitively unimpaired individuals.
Jack CR; Wiste HJ; Algeciras-Schimnich A; Weigand SD; Figdore DJ; Lowe VJ; Vemuri P; Graff-Radford J; Ramanan VK; Knopman DS; Mielke MM; Machulda MM; Fields J; Schwarz CG; Cogswell PM; Senjem ML; Therneau TM; Petersen RC
Alzheimers Dement; 2024 Mar; 20(3):2143-2154. PubMed ID: 38265198
[TBL] [Abstract][Full Text] [Related]
36. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
[TBL] [Abstract][Full Text] [Related]
37. Brain Amyloid-β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease.
Li WW; Shen YY; Tian DY; Bu XL; Zeng F; Liu YH; Chen Y; Yao XQ; Li HY; Chen DW; Zhou FY; Yang H; Li QM; Bao WQ; Guan YH; Zhou HD; Jin RB; Wang YJ
J Alzheimers Dis; 2019; 69(1):169-178. PubMed ID: 30958377
[TBL] [Abstract][Full Text] [Related]
38. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
Janelidze S; Bali D; Ashton NJ; Barthélemy NR; Vanbrabant J; Stoops E; Vanmechelen E; He Y; Dolado AO; Triana-Baltzer G; Pontecorvo MJ; Zetterberg H; Kolb H; Vandijck M; Blennow K; Bateman RJ; Hansson O
Brain; 2023 Apr; 146(4):1592-1601. PubMed ID: 36087307
[TBL] [Abstract][Full Text] [Related]
39. Two-Year Prognostic Utility of Plasma p217+tau across the Alzheimer's Continuum.
Feizpour A; Doré V; Doecke JD; Saad ZS; Triana-Baltzer G; Slemmon R; Maruff P; Krishnadas N; Bourgeat P; Huang K; Fowler C; Rainey-Smith SR; Bush AI; Ward L; Robertson J; Martins RN; Masters CL; Villemagne VL; Fripp J; Kolb HC; Rowe CC
J Prev Alzheimers Dis; 2023; 10(4):828-836. PubMed ID: 37874105
[TBL] [Abstract][Full Text] [Related]
40. Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome.
Petersen ME; Rafii MS; Zhang F; Hall J; Julovich D; Ances BM; Schupf N; Krinsky-McHale SJ; Mapstone M; Silverman W; Lott I; Klunk W; Head E; Christian B; Foroud T; Lai F; Diana Rosas H; Zaman S; Wang MC; Tycko B; Lee JH; Handen B; Hartley S; Fortea J; O'Bryant S;
J Alzheimers Dis; 2021; 79(2):671-681. PubMed ID: 33337378
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
